Skip to main content

Table 10 Adverse events and adverse drug reactions with an incidence of 5 % or more

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Adverse Events

120 μg

240 μg

Placebo

Headache

5 (13.9 %)

Nasopharyngitis

11 (26.8 %)

Nasopharyngitis

8 (22.9 %)

Nasopharyngitis

4 (11.1 %)

Headache

7 (17.1 %)

Pruritus

3 (8.6 %)

Back pain

3 (8.3 %)

Diarrhea

5 (12.2 %)

Fever

3 (8.6 %)

Hyperkalemia

2 (5.6 %)

Malaise

3 (7.3 %)

Hyperkalemia

3 (8.6 %)

Dizziness

2 (5.6 %)

  

Influenza

2 (5.7 %)

Hypertension

2 (5.6 %)

  

Hyperkalemia

2 (5.7 %)

Upper respiratory tract inflammation

2 (5.6 %)

  

Muscle Spasm

2 (5.7 %)

Diarrhea

2 (5.6 %)

  

Genital Bleeding

2 (5.7 %)

Vomiting

2 (5.6 %)

    

Arthralgia

2 (5.6 %)

    

Adverse drug reactions

120 μg

240 μg

Placebo

Hypertension

2 (5.6 %)

Headache

6 (14.6 %)

Genital Bleeding

2 (5.7 %)

  

Malaise

3 (7.3 %)

  
  1. (): Incidence rate